Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Baudax Bio Announces Corporate Update
Baudax Bio to Participate in the H.C. Wainwright Global Investment Conference
Baudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
Baudax Bio Acquires TeraImmune, Inc.
Baudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000
Baudax Bio Announces Date of Reconvened Annual Meeting
Baudax Bio Reports First Quarter Financial Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.